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Oral Squamous Cell Carcinoma (OSCC) is biologically characterized by the accumulation of multiple genetic and 
molecular alterations that end up clinically characterized as a malignant neoplasm through a phenomenon known 
as multistep. The members of the Cip/Kip family, specifically p21Waf1/CIP1, are responsible for cell cycle control, 
blocking the transition from phase G1 to phase S. We made a search of articles of peer-reviewed Journals in 
PubMed/ Medline, crossing the keywords. The goal of this paper is to determine the relationship between p21Waf1/
CIP1 expression and several clinical and pathological aspects of OSCC, their relationship with p53 and HPV, as well 
as genetic alterations in their expression pattern, their use as a prognosis market in the evolution of precancer-
ous lesions and their roles in anticancer treatments. The results of p21WAF1/CIP1 expression in OSCC showed mixed 
results in terms of positivity/negativity throughout different studies. It seems that, although p21Waf1/CIP1 expression 
is controlled in a p53-dependent manner, coexpression of both in OSCC is not intrinsically related. Although the 
presence of HPV viral oncoproteins increases p21Waf1/CIP1 levels, the small number of studies, have forced us to 
disregard the hypothesis that HPV infected lesions that present better prognosis are due to a p21Waf1/CIP1–dependent 
control. The role of p21WAF1/CIP1 as cell-cycle regulator has been well described; however, its relationship to OSCC, 
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the clinical and pathological variables of tumors, HPV and different treatments are not entirely clear. Thus, it would 
be very interesting to pursue further study of this protein, which may have a significant value for the diagnosis, prog-
nosis and therapy of this type of tumors.
Key words: p21Waf1/CIP1, Cip/Kip type cell-cycle regulator, Oral squamous cell carcinoma (OSCC), p53, genetic al-
terations.
Introduction
Oral Squamous Cell Carcinoma (OSCC) is biologically 
characterized by the accumulation of multiple genetic 
and molecular alterations that end up clinically charac-
terized as a malignant neoplasm through a phenomenon 
known as multistep. The accumulation of damaged 
genetic material leads oral keratinocytes in an uncon-
trolled division of mutant cells (1).
Control of the cellular cycle is regulated by cyclins and 
cyclin-dependent kinases (CDK). The activity of these 
enzymes is restricted by the inhibiting action of two 
great (CDKI) inhibitor groups: the INK4 family, com-
prised by inhibitors p16, p15, p18 and p19; and the Cip/
Kip family, comprised by p27, p57 and  p21 (2). The 
members of the Cip/Kip family block activity of Cyclin/
CDK complexes, and specifically CDK2 in E/A-CDK2 
cyclin complexes. These CDKIs block cell-cycle transi-
tion from G1 phase to S phase (3) (Fig. 1). 
Fig. 1. Model of the molecular mechanisms underlying PKC-
mediated regulation of G1→S progression. The upper portion 
of the figure (above the black arrow indicating G0/G1→S pro-
gression) shows the consequences of PKC activation in early 
G1, while the lower portion (below the arrow) depicts events 
resulting from PKC activation in mid-to-late G1 phase (40).
p21Waf1/CIP1 was initially identified as a 21 kDa protein 
that inhibited activation of cyclin/CDK (Cip1) com-
plexe, later it was identified as an overexpressed gene 
in senescent cells, located at 6p21.1 (sdi1); furthermore 
p21 gene product, is transcriptionally activated by p53 
in case of damage to DNA (WAF1). p21 is regulated by 
two different pathways, through a p53-dependent path-
way (DNA damage leads to activation of p53 and upreg-
ulation of p21 causing cell cycle blockage in G1 phase 
with possible DNA repair or induction of apoptosis); 
and a p53-independent way, through which cell growth 
factors (platelet-derived growth factor, fibroblast and 
epidermal, but not the insulin growth factor that is able 
to induce p21 in p53-deficient cells in quiescence) (4).
We made a search of articles of peer-reviewed Journals 
in PubMed/ Medline, crossing the keywords. The goal 
of this paper is to determine the relationship between 
p21Waf1/CIP1 expression and several clinical and patho-
logical aspects of OSCC, their relationship with p53 and 
HPV, as well as genetic alterations in their expression 
pattern, their use as a prognosis marker in the evolu-
tion of precancerous lesions and their roles in anticancer 
treatments.
p21Waf1/CIP1 expression in OSCC and its correla-
tion with clinical and pathological parameters
The results of p21WAF1/CIP1 expression in OSCC showed 
mixed results in terms of positivity/negativity among 
different studies; although all agree that expression is 
entirely nuclear, unlike other CDKIs such as p16, in 
which nuclear/cytoplasm location results are variable 
(5-10). In Table 1, we can see the results of all the studies 
analyzing  p21Waf1/CIP1 expression by immunohisto-
chemistry (3,7,11-28) (Table 1).
As for p21 expression and its relationship with cell cy-
cle control, Neves Ada et al. (26), found no correlation 
between the D1 and p21 cyclin expression, although its 
high expression in high-grade tumors supports its role 
in proliferative activity. However, forced stimulation of 
CDK4 causes sequestration of p21 in cell lines, increas-
ing the risk of becoming OSCC, on the other hand the 
application of recombinant p21 in OSCC xenografts, 
has shown to cause delay in in vivo tumor growth (29).
Regarding the relationship with clinical-pathological 
parameters, the results are highly variable, thus Fillies 
et al. (2) accounted for a relationship between loss of 
p21 expression and a decrease in overall survival, they 
Med Oral Patol Oral Cir Bucal. 2013 Mar 1;18 (2):e219-25.                                                                                                                                                  p21Waf1/CIP1 in oral squamous cell carcinoma
e221
Study OSCC Cases % (n) Positivity Quantification 
 
 







60 % (9) 
 
P21 (-) 0-1 % 
P21 (±) 2-5 % 
P21 (+) 6-20 % 
P21 (++) 21-50 % 
P21 (+++) > 50 % 
Tatemoto et al (12)  
150 
 
28.7 % (43) 
P21 (+) > 10 % 
P21 (-) <10 % 
Yook et al (13)  
20 
 









68.6 % (36) 
 
P21 (-) <10 % 
P21 (+1) 10-30 % 
P21 (+2) 30-50 % 
P21 (+3) >50 % 
 




42.86 % (9) 
P21 (-) < 5 % 
P21 (+) 5-25 % 
P21 (++) 25-50 % 
P21 (+++) > 50 % 
 





91.43 % (32) 
 
P21 (-) 0% 
P21 (+) < 33 % 
P21 (++) 33-66 % 
P21 (+++) > 66 % 
 




82.4 % (70) 
 
P21 (1+) <20 % 
P21 (2+) 20-50 % 
P21 (3+) >50 % 
Kudo et al 18) 47 77 % (36) P21 (+) > 5 % 
P21 (-) < 5 % 
 




53 % (16) 
P21 (-) <10 % 
P21 (+1) 10-30 % 
P21 (+2) 30-50 % 
P21 (+3) >50 % 
Kapranos et al (3) 31 61.3 % (19) P21 (+) > 10 % 
P21 (-)  10 % 
Xie et al (20) 80 92 % (74) P21 (+)  5 % 
P21 (-) < 5 % 
Yen-Ping et al (21)  
43 
 
72 % (31) 
P21 (-) 0 % 
P21 (+) < 10 % 
P21 (++) 11-50 % 
P21 (+++) 51-100 % 
Pande et al (22) 105 54 % (57) P21 (+) > 50 % 
P21 (-) < 50 % 
 
 






88.57 % (31) 
 
P21 (0) < 1 % 
P21 (1+) 1-10 % 
P21 (2+) 10-35 % 
P21 (3+) 36-70 % 
P21 (4+) >70 % 
Choi et al (24) 30 96.6 % (29) P21 (+)  10 % 
P21 (-) < 10 % 
 
Table 1. p21Waf1/CIP1 Immunohistochemical expression in OSCC.










43.6 % (23) 
 
P21 (-) < 25 % 
P21 (+) 25-50 % 
P21 (++) 50-75 % 
P21 (+++) > 75 % 
 
 






78.6 % (22) 
P21 (0) <1 % 
P21 (1) 1-10 % 
P21 (2) 10-20 % 
P21 (3) 20-30 % 
P21 (4) 30-40 % 
P21 (5) >40 % 
Nemes et al (7) 106 61.3 % (65) P21 (+) >10 % 
P21 (-)  10 % 
 




57.1 % (20) 
P21 (0) 0-19 % 
P21 (1) 20-39 % 
P21 (2) 40-59 % 
P21 (3) 60-100 % 
 




100 % (34) 
P21 (-) 0 % 
P21 (+) < 25 % 
P21 (++) 25-50 % 




OSCC: oral squamous cell carcinoma
also found an inverse correlation with tumor size. Tate-
moto et al. (12), found no association between p21 ex-
pression with tumor stage, mode of invasion of tumor 
cells and the differentiation of the same. However, they 
found a correlation with the presence of metastases in 
lymph nodes, 25 cases (38,5%) of positive nodes and 
18 cases (21.2%) of lymph nodes with negative tumor 
cells. According to Kapranos et al. (3), p21 shows posi-
tive expression in patients with HNSCC > 65 years, in 
chemotherapy-responsive tumors and stage III patients 
with a higher overall survival rate. According to Xie et 
al. (20), there is an inverse correlation between T classi-
fication and clinical stage, but not with N classification. 
Patients with p21 (+) tumors showed a greater disease-
free interval than those patients with negative p21. The 
Hungarian group led by Nemes et al. (7), found a cor-
relation between the expression of p21 and T3 and T4 
stage tumors, positive lymph-node metastasis, cancer in 
advanced stages (III and IV) and tumors in the tongue 
and the retromolar trigone. On the other hand, Ng et 
al. (17), found no relation between p21 expression and 
TNM classification, but they reported a correlation in 
actively proliferating tumors, older patients and women. 
Yen-Ping et al. (21), reported no correlation between p21 
expression and age, sex, oral habits, tumor location or 
TNM status, however they found a relationship between 
p21 (+) and a worse overall survival. 
Other authors found no relationship between p21 expres-
sion and the clinical-pathological variables under study 
(22,25). Osaki et al. (30), found the same expression of p21 
in well-controlled tumors than in lethal tumors, however 
they found no correlation with treatment failure or meta-
static sites. According to González-Moles et al. (25), p21 
expression is aberrant in all samples of non-tumoral adja-
cent epithelium and the absence of expression or decreased 
expression in tumors does not influence patient survival. 
Kuropkat et al. (23), found no relation between survival or 
time and recurrence. Yook et al. (13), found no correlation 
with any of the clinical-pathological parameters. 
p21Waf1/CIP1 and its relation with p53 expression
As mentioned above, p21 is regulated in two different 
ways; either through a p53-dependent pathway or a 
p53-independent one, so it is very important to es-
tablish the relationship between these two proteins 
in OSCC.
For van Oijen et al. (11) and  Nemes et al. (7) the expres-
sion of p21 is independent of the presence of functional 
p53 in head and neck tumors (HNSCC) but its expres-
sion is related to the differentiation of tumors. In some 
tumors, p21 was expressed even in proliferating cells in 
which cyclin D1 was also expressed, suggesting that the 
inhibitory effect of p21 is offset by D1 cyclin expression 
in these tumors. 
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In this regard, Brennan et al. (4), found that the accumu-
lation of nitric oxide synthase-2 (NOS2), which causes 
programmed cell death via p53 through p21 expression, 
from the 10.3 pmol NO min-1 mg protein-1, was sufficient 
to cause apoptosis by a p53-independent pathway, thanks 
to p21 expression. This data, together with the findings of 
Yook et al. (13), who reported that p21 expression was not 
associated with mutated p53 or with p53 protein overex-
pression, therefore supported the theory above, namely 
p21 expression by a p53-independent pathway. 
Ng et al. (17) found no correlation between the p21 and 
p53 expression, on the other hand they found a relationship 
with mdm2 expression, an oncogene with self-regulating 
effect of the normal p53 expression. Similarly, Kudo et al. 
(18), found no association between p21 and p53. 
If we address p53/p21 status and its relationship with 
clinical-pathological parameters, according to Kapranos 
et al.  (3) patients with p53(-)/p21 (+) tumors showed the 
highest survival rates, whereas p53(+)/p21(-) had a lower 
overall survival (3). Yen-Ping et al (21), found the high-
est 5-year survival rate in the p53(-)/p21(-) group and the 
lowest in the p53(+)/p21(+) group. According to Xie et al. 
(20) the disease-free period increased when the tumors 
were p53(-) as well as being p21 (+). Yanamoto et al. (31), 
found that p53(+)/p21(+) tumors showed the worst clini-
cal behavior in terms of survival. Agarwal et al. (14), in a 
total of 51 tumors, found that 58.8% were p53(+)/p21(+), 
while 17.7% of tumors were p53(-)/ p21(-), thus indicating 
the high heterogeneity of expression of these proteins in 
OSCC. Kudo et al. (18), described the highest percent-
age of survival for p53(-)/p21(+) tumors and the lowest for 
p53(+)/p21(+) tumors, as well as Yanamoto et al. (31).
p21Waf1/CIP1 expression in precancerous lesions 
and the role of HPV 
In the dysplastic epithelium, p21 increases its expres-
sion as the degree of dysplasia increases.  In OSCC, 
expression is variable, especially in poorly differenti-
ated tumor areas. They found no association whatso-
ever with any clinical-pathological feature. Agarwal et 
al. (14), found a rising percentage of p21 expression as 
hyperplasia is transformed into dysplasia, associated 
with differentiation and proliferative activity. Kudo et 
al. (18), found among 24 epithelial dysplasias, 23 (96%) 
were positive for p21, compared to 77% (36 of 47) of 
OSCC. Furthermore, 79% of these dysplasias were 
p53(-)/p21(+) compared with 25% of OSCC. Queiroz 
et al. (28), found no statistically significant differenc-
es between p21 expression in normal oral epithelium, 
oral squamous papilloma and OSCC. Chang et al. (32), 
found a group of 53 verrucose leukoplakias, reporting 
p21 expression in 75% (40) of cases; 42% (22) developed 
OSCC in a period of three and a half years; 26% (14) 
were recurrent and 32% (17) were free of disease. Aber-
rant p21 positivity was associated with 80% progres-
sion to OSCC compared with 32% of recurrences. On 
the other hand, Hogmo et al. (33), found no relationship 
between p21 expression and risk assessment in terms of 
precancerous lesions.
As regards to the detection of HPV in OSCC and the 
expression of cell-cycle proteins, it seems that the E7 
oncoprotein in high-risk HPV causes cell cycle dysreg-
ulation through the interaction of AP-1 complex tran-
scription and CDKIs such as p27 and p21. Soares et al. 
(34), found that 11 out of 33 cases (33.33%) were posi-
tive for HPV18 (81.81%) or HPV16 (18.19%). Of these, 
p21 expression was positive in 5 of 11 cases(45.45%); 
they found no statistically significant association. 
Genetic alterations in p21Waf1/CIP1 expression 
pattern
As regards to the genetic alterations of p21 in OSCC, 
Ralhan et al. (19), described polymorphism at codon 149 
(A→G) in 11 of 30 premalignant lesions (37%) (7 hyper-
plastic lesions and 4 dysplastic lesions) and in 11 out of 30 
OSCCs (37%); being statistically significant compared to 
normal oral mucosa. It appears that this polymorphism is 
more common in precancerous lesions (10 of 11) and in 
OSCC (11 of 11) with weak p53 in lesions with mutated 
p53, suggesting that this polymorphism may affect the 
p53 pathway and play an important role in tumorigen-
esis. Gomes et al. (35), studied the relationship between 
p21WAF1/C98A polymorphism and its genotypes in 
OSCC. Thus, genotype CA showed a relative risk of ma-
lignant transformation 1.57 compared to CC genotype. 
Similarly, they showed that the heterozygous genotype 
has a higher immunopositivity CA (mean 56.75) and CC 
(mean 37.65) in a statistically significant way. 
The frequency of mutations (transitions and transver-
sions) in exon 2 of p21, according to Ibrahim et al. (36), 
ranges from 14-43% depending on the origin of tumors, 
being higher for Sudanese toombak-dippers tumors. 
In any case, the loss of 9p21 and its relationship with 
clinical-pathological parameters, can only be estimated 
in the context of the complex pattern of genomic im-
balances that accompanies loss of chromosomes in the 
examined tumors.
The role of p21Waf1/CIP1 in anticancer treatments 
The induction of differentiation and anticancer agents 
remains today as the most appropriate strategy in cancer 
treatments, although in clinical practice results are in-
sufficient. The mechanism of action of these molecules 
and agents in relation to p21 is not fully understood. Ac-
cording to Yoneda et al. (37), vesnarinone, a differen-
tiation inducing agent inhibits cell growth and induces 
accumulation of cells in G1 phase without taking into 
account the existence of mutations in p53. Vesnarinone 
suppresses p21 promoter activity but produces p21-mR-
NA stabilization during a long period of time, therefore 
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p21 protein expression is induced several hours after 
drug administration. The induction of p21 blocks cyc-
lin E and suppresses the activity of the cyclin E/CDK2 
complex, inhibiting pRb phosphorylation.
The mechanism of action of 5-FU (5-fluorouracil) and 
γ-rays, consists of an apoptotic effect of tumor cells 
yet in a p53 and p21 independent manner. According 
to Yoneda et al. (38), although p21-mRNA levels are 
increased with both agents, p21 protein was expressed 
only in parallel with increasing doses of radiation but not 
with 5-FU. According to this same group, in the case of 
TGF-β, there was an increase in p21 promoter activity in 
7 of 9 cell lines in OSCC, while p21 protein expression 
increased sharply. However, when cells are transfected 
with Mn-SOD (Manganese Superoxide Dismutase), a 
potent proapoptotic agent derived from the action of 
various anti-tumoral agents such as 5-FU, PLM (a bleo-
mycin derivative), CDDP (cis-diamminedichloroplati-
num) and γ-rays, which after transfection of Mn-SOD, 
p21 expression increases dramatically inducing apopto-
sis of OSCC cell lines by p53-independent pathway. 
These same results, in which there is an increase in 
p21 expression with cell-cycle blockage, have been de-
scribed for perifosine (a new alkylphospholipid) , phe-
noxodial (a new isoflavone), EGCG (epigallocatechin-3
-gallate, a polyphenol from green tea), SFN (sulforap-
hane) and also for cyclosporine A, growth inhibitory 
doses of EGF   and X radiation (39).
As we have seen, the role of p21WAF1/CIP1 as cell-cycle 
regulator has been well described; however, its relation-
ship to OSCC, clinical and pathological variables of the 
tumors, HPV and different treatment modalities are 
not entirely clear. Thus, it would be very interesting to 
pursue further study of this protein, which may have a 
significant value in terms of diagnosis, prognosis and 
therapy in this type of tumors.
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